Cellnovo (EPA:CLNV) and Diabeloop said this week they are launching a CE Mark cross-over registration study for an artificial pancreas device Diabeloop is developing which uses Cellnovo’s insulin pump.
The registration study aims to generate appropriate security & safety data as the company seeks CE Mark approval for the Diabeloop artificial pancreas combined with Cellnovo’s CGM some time in 2018, the companies said.
Read the whole story at our sister site, Drug Delivery Business
The post Cellnovo, Diabeloop launch artificial pancreas CE Mark trial appeared first on MassDevice.
from MassDevice http://ift.tt/2q04nML
Cap comentari:
Publica un comentari a l'entrada